tldrdailynews.com logo

Lilly's 'Triple-G' Obesity Drug Shows Strong Results in Alleviating Fatty Liver Disease.

1 min read
Source: STAT
Lilly's 'Triple-G' Obesity Drug Shows Strong Results in Alleviating Fatty Liver Disease.
Photo: STAT
TL;DR

Eli Lilly's experimental obesity drug, retatrutide, significantly reduced liver fat in a small clinical trial of 98 patients with nonalcoholic fatty liver disease. Patients on the highest dose experienced an 86% decrease in liver fat over 48 weeks, with 93% achieving resolution of the disease. The results support further studies of the treatment against the increasingly common condition that lacks approved treatments.

Topics:businesshealth#clinical-trial#eli-lilly#health#liver-fat#nonalcoholic-fatty-liver-disease#obesity-drug
Share this article
  1. Fatty liver disease was alleviated by Lilly's 'triple-G' obesity drug  STAT
  2. A new weight-loss drug dubbed the 'triple G' could be stronger than Ozempic, Wegovy, and Mounjaro — and as powerful as bariatric surgery  Yahoo Life
  3. Eli Lilly (LLY) Weight-Loss Shot Gives Company's Strongest Results in Trial  Bloomberg
  4. Triple Agonist Retatrutide Hits New Weight-Loss Highs  Medscape
  5. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial  The Lancet

Want the full story? Read the original reporting

Read on STAT